Abstract:Objective: To explore pharmaceutical care model provided by clinical pharmacists in renal transplant recipients under precision medicine system. Methods: The practice and role of precision pharmaceutical care Methods in renal transplant recipients were introduced, such as gene test technology, clinical pharmacokinetic monitoring. Results: By using gene test technology, clinical pharmacists assisted clinical physicians to adjust the therapeutic regimen of tacrolimus, monitor treatment drugs, and guide rational drug use. Conclusion: Precision pharmaceutical care can effectively provide patients with optimal dosing regimens, promote rational drug use.
杨辉,崔向丽,杨婧,刘丽宏. 临床药师对1例肾移植受者精准化药学服务分析[J]. 临床药物治疗杂志, 2017, 15(6): 60-63.
YANG Hui, CUI Xiang-li, YANG Jing, LIU Li-hong. Precision pharmaceutical care in a case of renal transplant recipient offered by clinical pharmacists. CLINICAL MEDICATION JOURNAL, 2017, 15(6): 60-63.
[1] Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey [J]. Lancet, 2012, 379 (9818): 815-822.
[2] 李新长, 孟栋良, 龙成美, 等. 肾移植受者CYP3A5基因多态性对他克莫司血药浓度及疗效的影响[J]. 中国组织工程研究, 2012, 16(18): 3255-3258.
[3]. Tada H, Tsuchiya N, Satoh S, et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients [J]. Transplant Proc, 2005, 37(4): 1730-1732.
[4] Ninova D, Covarrubias M, Rea D J, et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-beta1 and alpha-smooth muscle actin [J]. Transplantation, 2004, 78(3): 338-344.
[5] Ball S E, Scatina J, Kao J, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4 [J]. Clin Pharmacol Ther, 1999, 66(3): 288-294.
[6] Cheung C Y, Op den Buijsch R A, Wong K M, et al. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients [J]. Pharmacogenomics, 2006, 7(4): 563-574.
[7] 朱琳, 宋洪涛, 王庆华, 等. CYP3A4*18B 和CYP3A5*3 基因多态性对肾移植患者他克莫司剂量及浓度的影响[J]. 药学学报, 2012, 47(7): 878-883.
[8] 王明丽, 吴萍, 罗光华, 等. 基因多态性与他克莫司血药浓度的相关性研究[J]. 中国药房, 2010, 21(46): 4343-4346.
[9] Wei-lin W, Jing J, Shu-sen Z, et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients[J]. Liver Transpl, 2006, 12(5): 775-780.
[10] Uesugi M, Masuda S, Katsura T, et al. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients [J]. Pharmacogenet Genomics, 2006, 16(2): 119-127.
[11] Zhao C Y, Jiao Z, Mao J J, et al. External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients [J]. Br J Clin Pharmacol, 2016, 81(5): 891-907.
[12] Birdwell K A, Decker B, Barbarino J M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing [J]. Clin Pharmacol Ther, 2015, 98(1): 19-24.
[13] 徐芳, 翟所迪, 胡永芳. 他克莫司发生药物相互作用的分子机制[J]. 中国药学杂志, 2007, 42(13): 965-968.
[14] 刘艺平, 戴立波, 李换德, 等. 影响他克莫司疗效的相关因素分析[J]. 中国医院药学杂志, 2011, 31(5): 405-407.
[15] Vavic N, Rancic N, Dragojevic-Simic V, et al. The influence of comedication on tacrolimus blood concentration in patients subjected to kidney transplantation: a retrospective study [J]. Eur J Drug Metab Pharmacokinet, 2014, 39(4): 243-253.
[16] Hesselink D A, Ngyuen H, Wabbijn M, et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids [J]. Br J Clin Pharmacol, 2003, 56(3): 327-330.
[17] Anglicheau D, Flamant M, Schlageter M H, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation[J] .Nephrol Dial Transplant, 2003, 18(11): 2049-2414.
[18] Kuypers D R, Peeters P C, Sennesael J J, et al. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring [J]. Transplantation, 2013, 95(2): 333-340.
[19] Cheung C Y, Op den Buijsch R A, Wong K M, et al. Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients [J]. Pharmacogenomics, 2006, 7(4): 563-574.
[20] Stifft F, Stolk L M, Undre N, et al. Lower variability in 24-hour exposure during once-daily compared to twicedaily tacrolimus formulation in kidney transplantation [J]. Transplantation, 2014, 97(7): 775-780.
[21] Wlodarczyk Z, Squifflet J P, Ostrowski M, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial [J]. Am J Transplant, 2009, 9 (11): 2505-2513.
[22] Satoh S, Niioka T, Kagaya H, et al. Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation [J]. Pharmacogenomics, 2014, 15(11): 1495-1506.
[23] 中华医学会器官移植学分会, 中国医师协会器官移植医师分会. 中国肾移植受者免疫抑制治疗指南[J]. 器官移植, 2016, 7(5): 1-4.